PuzzleheadedBid7612





















  1. Expect CLVS to have a horrible Q2! CLVS will miss on EPS and revenue! Expect the same Sell Off as Q1 another 23%

  2. Expect CLVS to have a horrible Q2! CLVS will miss on EPS and revenue! Expect the same Sell Off as Q1 another 23%

  3. CLVS fails to beat on EPS and revenue, shares of CLVS will plummet on Monday Morning! Expect a repeat of Q1!

  4. Wait, you haven’t covered your short position yet? As a professional courtesy, you should review the sales figures for Q2 that were announced last week for Olaparib and Niraparib. Similar drugs as Rucaparib.

  5. Expect CLVS to have a horrible Q2! CLVS will miss on EPS and revenue! Expect the same Sell Off as Q1 another 23%

  6. Expect CLVS to have a horrible Q2! CLVS will miss on EPS and revenue! Expect the same Sell Off as Q1 another 23%

  7. CLVS fails to beat on EPS and revenue, shares of CLVS will plummet on Monday Morning! Expect a repeat of Q1!

  8. CLVS fails to beat on EPS and revenue, shares of CLVS will plummet on Monday Morning! Expect a repeat of Q1!

  9. Expect CLVS to have a horrible Q2! CLVS will miss on EPS and revenue! Expect the same Sell Off as Q1 another 23%

  10. Do the research I did, their sales are dismal! CLVS has done nothing to increase share value! Once again CLVS will FAIL to beat on EPS, and misses on revenue! CLVS fails to beat market projections for Q2! Expect another 24% decline in share price

  11. Expect CLVS to have a horrible Q2! CLVS will miss on EPS and revenue! Expect the same Sell Off as Q1 another 23%

  12. Do the research I did, their sales are dismal! CLVS has done nothing to increase share value! Once again CLVS will FAIL to beat on EPS, and misses on revenue! CLVS fails to beat market projections for Q2! Expect another 24% decline in share price

  13. Taken from Bloomberg-Expect CLVS to repeat the same negative earnings for Q2! Rubraca sales are horrible, CLVS fails to meet EPS, and earnings! Shares of Clovis Oncology (NASDAQ:CLVS) are down 23% in Wednesday morning trading after its Q1 2022 results missed on both the top and bottom lines amid a decline in sales of its key product Rubraca (rucaparib)

  14. CLVS sales for Rubraca are dismal! CLVS will FAIL to beat on EPS, and will miss on revenue! CLVS fails to beat market projections for Q2! Expect another 24% decline in share price!

  15. CLVS sales for Rubraca are dismal! CLVS will FAIL to beat on EPS, and will miss on revenue! CLVS fails to beat market projections for Q2! Expect another 24% decline in share price!

  16. Do the research I did, their sales are dismal! CLVS has done nothing to increase share value! Once again CLVS will FAIL to beat on EPS, and misses on revenue! CLVS fails to beat market projections for Q2! Expect another 24% decline in share price

Leave a Reply

Your email address will not be published. Required fields are marked *